anti-CD19 CAR NK cells

Phase 2Cell therapy

PPersonGen BioTherapeutics (Suzhou) Co., Ltd.

anti-CD19 CAR NK cells is one of 209 biologic programs targeting Systemic Lupus Erythematosus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

208

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusRecruiting

Central Nervous System LymphomaEnrolling by invitation

Autoimmune DiseaseRecruiting

Rheumatoid ArthritisRecruiting

Immune ThrombocytopeniaRecruiting

Cell TherapyNot yet recruiting

AutoimmuneRecruiting

NephropathyRecruiting

Systemic Lupus ErythematosusPhase 1

Recruiting

Central Nervous System LymphomaPhase 1

Enrolling by invitation

Autoimmune DiseasePhase 1

Recruiting

Rheumatoid ArthritisPhase 1

Recruiting

Immune ThrombocytopeniaPhase 1

Recruiting

Cell TherapyPhase 2

Not yet recruiting

AutoimmunePhase 1

Recruiting

NephropathyPhase 1

Recruiting

Competition

Competitive Landscape

176 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

anti-CD19 CAR NK cells

PPersonGen BioTherapeutics (Suzhou) Co., Ltd.

Phase 2

1 2

Actos

Takeda

Preclinical

2 3

Celexa

AbbVie

Preclinical

1 4

Voltaren

Cataflam

Plaquenil

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 8

Velcade

SShilpa Grover, MD, MPH

Preclinical

2 9

Disalcid

JJoslin Diabetes Center

Preclinical

—10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Not yet recruiting

Cell Therapy

NCT06631040

Q1 2027

Phase 1Recruiting

Autoimmune

NCT06318533

Q2 2027

Phase 1Recruiting

Nephropathy

NCT06469190

Q3 2027

Phase 1Recruiting

Systemic Lupus Erythematosus

NCT06010472

Clinical

Trials by Indication[1]

Lymphoma2 trials

Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

Unknown status·AAllife Medical Science and Technology Co., Ltd.·Phase 1·NCT03690310·9 enrolled

The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma

Unknown status·—·Phase 1·NCT05673447·12 enrolled

Systemic Lupus Erythematosus2 trials

Anti-CD19 CAR-NK Cells in Refractory/Relapsed Systemic Lupus Erythematosus

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT06421701·10 enrolled

An Exploratory Clinical Study of Anti-CD19 CAR NK Cells in the Treatment of Systemic Lupus Erythematosus

Recruiting·—·Phase 1·NCT06010472·36 enrolled

Central Nervous System Lymphoma1 trial

Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma

Enrolling by invitation·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT06827782·42 enrolled

Autoimmune Disease1 trial

An Exploratory Clinical Study of CD19 CAR NK Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

Recruiting·—·Phase 1·NCT06464679·72 enrolled

Rheumatoid Arthritis1 trial

An Exploratory Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Antisynthetase Antibody Syndrome and Rheumatoid Arthritis

Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 1·NCT06613490·24 enrolled

5 more indications

Leukemia1 trial

PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma

Unknown status·PPersonGen BioTherapeutics (Suzhou) Co., Ltd.·Phase 1/2·NCT02892695·10 enrolled

Cell Therapy1 trial

Cell Therapy with Anti-CD19 CAR-NK Cells in Patients with Relapsed or Resistant B-ALL

Not yet recruiting·SShahid Beheshti University of Medical Sciences·Phase 1/2·NCT06631040·10 enrolled

Immune Thrombocytopenia1 trial

An Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Primary Immune Thrombocytopenia

Recruiting·—·Phase 1·NCT06337474·9 enrolled

Autoimmune1 trial

An Exploratory Clinical Study of the Safety and Efficacy of Chimeric Antigen Receptor NK Cell Injections for the Treatment of Relapsed/Refractory B-cell Related Autoimmune Diseases

Recruiting·YYANRU WANG·Phase 1·NCT06318533·15 enrolled

Nephropathy1 trial

An Exploratory Clinical Study of the Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor NK Cell Injections (KN5501) in the Treatment of Relapsed/Refractory Immune Nephropathy

Recruiting·CChanghai Hospital·Phase 1·NCT06469190·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for anti-CD19 CAR NK cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — anti-CD19 CAR NK cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for anti-CD19 CAR NK cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — PersonGen BioTherapeutics (Suzhou) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: PPersonGen BioTherapeutics (Suzhou) Co., Ltd.

anti-CD19 CAR NK cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2027

Q3 2027

Trials by Indication[1]

Lymphoma2 trials

Systemic Lupus Erythematosus2 trials

Central Nervous System Lymphoma1 trial

Autoimmune Disease1 trial

Rheumatoid Arthritis1 trial

Leukemia1 trial

Cell Therapy1 trial

Immune Thrombocytopenia1 trial

Autoimmune1 trial

Nephropathy1 trial

References

Drug Info

Quick Facts

Related News